Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)
31.18
+0.48 (1.56%)
Sep 30, 2026, 3:04 PM CST
SHE:300584 Revenue
Nanjing Hicin Pharmaceutical had revenue of 203.81M CNY in the quarter ending June 30, 2026, with 22.84% growth. This brings the company's revenue in the last twelve months to 726.62M, up 26.06% year-over-year. In the year 2025, Nanjing Hicin Pharmaceutical had annual revenue of 671.05M with 33.05% growth.
Revenue (ttm)
726.62M
Revenue Growth
+26.06%
P/S Ratio
5.15
Revenue / Employee
1.31M
Employees
553
Market Cap
3.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 671.05M | 166.69M | 33.05% |
| Dec 31, 2024 | 504.36M | -13.47M | -2.60% |
| Dec 31, 2023 | 517.83M | -8.63M | -1.64% |
| Jan 1, 2023 | 526.47M | -51.85M | -8.97% |
| Jan 1, 2022 | 578.32M | -127.98M | -18.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 23.66B |
| Zhejiang Starry Pharmaceutical | 2.46B |
| Nanjing Well Pharmaceutical Group | 1.40B |
| Zhuhai Rundu Pharmaceutical | 1.34B |
| Huaren Pharmaceutical | 1.30B |
| Qianjiang Yongan Pharmaceutical | 979.49M |
| Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD | 737.90M |
| Zhejiang Yatai Pharmaceutical | 328.58M |